12/16
04:37 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:09 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
07:10 am
imux
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]
Low
Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]
11/26
06:30 am
imux
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Low
Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
11/21
05:31 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/14
08:09 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/13
09:01 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/13
06:30 am
imux
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/7
08:45 am
imux
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
10/29
06:30 am
imux
Immunic to Participate in Industry and Investor Conferences in November
Medium
Report
Immunic to Participate in Industry and Investor Conferences in November
10/22
04:04 am
imux
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage [Yahoo! Finance]
Low
Report
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage [Yahoo! Finance]
10/18
07:31 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
Low
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
10/8
12:25 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immunic (NASDAQ:IMUX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/2
10:42 am
imux
Positive Signs As Multiple Insiders Buy Immunic Stock [Yahoo! Finance]
Low
Report
Positive Signs As Multiple Insiders Buy Immunic Stock [Yahoo! Finance]
10/1
06:38 am
imux
Immunic to Participate in Scientific and Investor Conferences in October [Yahoo! Finance]
Medium
Report
Immunic to Participate in Scientific and Investor Conferences in October [Yahoo! Finance]
10/1
06:30 am
imux
Immunic to Participate in Scientific and Investor Conferences in October
High
Report
Immunic to Participate in Scientific and Investor Conferences in October
9/29
08:05 am
imux
Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
9/26
08:05 am
imux
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.